

Attorney Docket No.: 5697.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Murray et al.

Application No.: 09/551,740

Group Art Unit: 1625

Filed: April 18, 2000

Examiner: Robinson, B.

Confirmation No: 2226

For: New Compounds, Their Preparation and Use

**CERTIFICATE OF FACSIMILE TRANSMISSION**Assistant Commissioner for Patents  
Washington, DC 20231

Sir:


I hereby certify that the attached correspondence comprising

1. RCE Transmittal
2. Amendment

was sent to the United States Patent Office by telefax to the attention of Examiner B. Robinson, fax number (703) 308-7922.

Respectfully submitted,

Date: December 9, 2002



---

Cheryl H. Agis, Reg. No. 34,086  
Outside Counsel  
Novo Nordisk of North America, Inc.  
405 Lexington Avenue, Suite 6400  
New York, NY 10174-6401  
(212) 867-0123

Attorney Docket No.: 5697.200-US

PATENT

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Murray et al.

Application No.: 09/551,740

Group Art Unit: 1625

Filed: April 18, 2000

Examiner: Robinson, B.

Confirmation No: 2226

For: New Compounds, Their Preparation and Use

**REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL**

Commissioner for Patents  
Box RCE  
Washington, DC 20231

Sir:

This is a request for Continued Examination (RCE) under 37 C.F.R. §1.114 of the above identified application.

**1. Submission required under 37 C.F. R. § 1.114****a. ☐ Previously submitted**

- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on
- ii. ☐ Consider the arguments in the Appeal Brief of Reply Brief previously filed on
- iii. ☐ Other

**b. ☒ Enclosed**

- i. ☒ Amendment / Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other

**2. Miscellaneous**

a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of \_\_\_\_\_ months. (period of suspension shall not exceed 3 months, Fee under 37 C.F.R. § 1.17 (i) required)

b. ☐ Other

3. In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee,

Attorney Docket No.: 5697.200-US

PATENT

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

 13  
 VCB  
 12-10

In re Application of: Murray et al.

Application No.: 09/551,740

Group Art Unit: 1625

Filed: April 18, 2000

Examiner: Robinson, B.

Confirmation No: 2226

For: New Compounds, Their Preparation and Use

## REQUEST FOR CONTINUED EXAMINATION (RCE) TRANSMITTAL

Commissioner for Patents  
 Box RCE  
 Washington, DC 20231

Sir:

This is a request for Continued Examination (RCE) under 37 C.F.R. § 1.114 of the above identified application.

### 1. Submission required under 37 C.F. R. § 1.114

#### a. ☐ Previously submitted

- i. ☐ Consider the amendment(s)/reply under 37 C.F.R. § 1.116 previously filed on
- ii. ☐ Consider the arguments in the Appeal Brief of Reply Brief previously filed on
- iii. ☐ Other

#### b. ☒ Enclosed

- i. ☒ Amendment / Reply
- ii. ☐ Affidavit(s)/Declaration(s)
- iii. ☐ Information Disclosure Statement (IDS)
- iv. ☐ Other

### 2. Miscellaneous

- a. ☐ Suspension of action on the above-identified application is requested under 37 C.F.R. § 1.103 (c) for a period of \_\_\_\_\_ months. (period of suspension shall not exceed 3 months) Fee

#### b. ☐ Other

3. In the event that an extension of time is required, Applicant hereby petitions for such extension of time. The Commissioner of Patents is authorized to charge the required fee

if applicable, to Deposit Account 14-1447.

4. Fees-The RCE fee under 37 C.F.R. §1.17 (e) is required by 37 C.F.R. §1.114 when the RCE is filed.

a. ☒ The Director is hereby authorized to charge the following fees, or credit any overpayments, to Deposit Account No. 14-1447.

- i. ☒ RCE fee required under 37 C.F.R. § 1.17 (e)
- ii. ☐ Extension of time fee (37 C.F.R. §§ 1.136 and 1.17)
- iii. ☐ Other

Respectfully submitted,



Cheryl H. Agris, Reg. No. 34,086  
Outside Counsel for  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540

Date: December 9, 2002